Pulmonx Corp (LUNG)
6.79
+0.37
(+5.76%)
USD |
NASDAQ |
Nov 22, 16:00
6.80
+0.01
(+0.15%)
After-Hours: 20:00
Pulmonx Research and Development Expense (Quarterly): 3.744M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.744M |
| June 30, 2024 | 5.615M |
| March 31, 2024 | 4.21M |
| December 31, 2023 | 3.896M |
| September 30, 2023 | 4.22M |
| June 30, 2023 | 5.71M |
| March 31, 2023 | 4.253M |
| December 31, 2022 | 3.903M |
| September 30, 2022 | 4.366M |
| June 30, 2022 | 3.594M |
| March 31, 2022 | 3.534M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.708M |
| September 30, 2021 | 2.815M |
| June 30, 2021 | 3.506M |
| March 31, 2021 | 3.034M |
| December 31, 2020 | 2.472M |
| September 30, 2020 | 1.997M |
| June 30, 2020 | 1.426M |
| March 31, 2020 | 1.565M |
| December 31, 2019 | 1.603M |
| September 30, 2019 | 1.399M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.426M
Minimum
Jun 2020
5.71M
Maximum
Jun 2023
3.458M
Average
3.651M
Median
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 4.353M |
| IRIDEX Corp | 1.299M |
| Stereotaxis Inc | 2.454M |
| Electromed Inc | 0.166M |
| Myomo Inc | 1.249M |